Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in Active Psoriatic Arthritis (Multicenter, Randomized, Double-blind, Placebo-controlled)
2004-003298-10Phase 3Terminated
- Sponsor
- Janssen Biotech
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Golimumab with Placebo (2 arms). Primary endpoints: ACR20 response at Week 14 and Radiographic progression at Week 24. Started Dec 2005; status: terminated.
02
Drugs
golimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2004-003298-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003298-10.